Zaiqi Wang is a physician scientist with board certified in both internal medicine and clinical pharmacology in USA. Over past 17 years, Zaiqi has directed/led drug development work at Eli Lilly, Schering-Plough, MSD, and Roche; from discovery to Phase IV across broad spectrum of therapeutic areas with a passion in translational medicine research.  He has been responsible for clinical research in MSD China development center from June 2011 until he joined Roche in July 2017.  Zaiqi has supported a number of IND and NDA submission and led a number of first-in-human programs over the years.  Zaiqi has directed 7 first-in-human programs while working at Schering-Plough, and led the early development team of VLA-4 at legacy Schering.  While at MSD China development over past 6 years, Zaiqi has been responsible for a number of CSAs, clinical studies and NDA approvals in China; including Gardasil (HPV vaccines), Bridion, Noxafil, Emend, oganlutran, and Janumet.  He has been the key driver the China development strategy and plan for Merck’s PD-1 Keytruda.   While at Roche, he is the site head for Roche Innovation Center in Shanghai, one of major full value chain discovery and early development site for Roche, to lead the drug discovery from medicinal chemistry to clinical proof of concept.

Zaiqi came to Merck in 2001 as an associate director of Early Clinical Research and Experimental Medicine for legacy Schering Plough. Before that, he worked at Eli Lilly as a principal investigator in Phase 1 Unit. Since joining Merck, Zaiqi has taken on roles of increasing responsibility and complexity and he had been promoted to the director of clinical research in 2004.  Zaiqi had contributed the development of a number of compounds across wide therapeutic areas. In 2009, he was appointed head of the Translational Medicine Unit in Singapore. In June 2011, Zaiqi has been name as the head of clinical research in MSD China. Throughout these roles, he has gained extensive experience in clinical development, and honed his problem-solving and managerial skills. Zaiqi has worked on both sponsor and investigative sides for early development.

Zaiqi earned his M.D. from Henan University inChinaand his Ph.D. in biochemistry from Virginia Polytechnic Institute and State University. He completed post-doctoral work at the Johns Hopkins University School of Medicine and at the Indiana University Medical Center. He has authored more than 20 papers in peer-reviewed journals.  He also serves on editorial board of Journal of “Clinical and Translational Science”.